ELEGEN’s Post

Explore the latest PNAS Special Feature on Nanoparticles for RNA Therapeutics, delving into the diverse strategies employed for the discovery and characterization of delivery systems in the realm of RNA therapeutics. https://ow.ly/EgBP50QUjFr

August 01st is World RNA Day! 🧬 But do you know why it's celebrated on this date? 🤔 Every strand of RNA is a sequence of four building blocks called nucleotides. The first three are adenine, uracil, guanine - A, U, and G. Put together in this order, these three nucleotides form a ‘codon’ that instructs the ribosome to start building the protein. Since this represents the starting instruction, so AUGust 01st has become associated with celebrating RNA!¹ Ready to learn more about RNA and it's importance for oncology research? Read our informative blog posts to explore RNA analysis methods, transcriptomic technology for mRNA profiling studies, and RNA-Seq Panels for preclinical drug development. 📄Choosing the Right RNA Analysis Methods: Genome-wide RNA-Seq vs. NanoString nCounter® vs. Targeted RNA-Seq Panel ➡️https://hubs.la/Q02JMf9m0 📄Genome-Wide RNA-seq and Array-Based NanoString Transcriptomic Technologies: Which to Use and When? ➡️ https://hubs.la/Q02JMf9l0 📄Leveraging Targeted Mouse I/O RNA-Seq Panels to Improve the Translatability of Immuno-Oncology Studies ➡️https://hubs.la/Q02JM2dm0 #WorldRNADay #RNAday #RNA #RNASeq ¹https://hubs.la/Q02JM6hx0

Revolutionizing Healthcare is something we do together. RNA therapeutics are changing the world of healthcare now but how see we and other scientists from the B-SMART and EXPERT project the future? They wrote a new Policy Paper to share their findings on the 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 & 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝗲𝘀 of RNA therapeutics. Visit the website to 𝗿𝗲𝗮𝗱 𝗮𝗻𝗱 𝗱𝗼𝘄𝗻𝗹𝗼𝗮𝗱 the Policy Paper: https://lnkd.in/dba4jkrA Why should you read it? 🧪Learn more about how B-SMART & EXPERT scientists are in the 𝗙𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 in RNA-based Therapeutics 🔬Be surprised about the 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 in a new wave of RNA Therapeutics 🥼𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 in today's RNA Therapeutics This paper is the work of 𝗺𝗮𝗻𝘆 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀, we would like to thank Professor Raymond Schiffelers who coordinates the 𝗕-𝗦𝗠𝗔𝗥𝗧 & 𝗘𝗫𝗣𝗘𝗥𝗧 project for his guidance.    Let us 𝗲𝗺𝗯𝗿𝗮𝗰𝗲 𝘁𝗵𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝘄𝗼𝗿𝗹𝗱 of RNA research filled with these challenges, every challenge is an opportunity to unravel the full potential of RNA. 

The Nanoparticles for RNA Therapeutics Special Feature focuses on RNA therapeutics and their delivery, highlighting the diverse approaches used to discover and characterize delivery systems. The articles focus on the delivery of RNA to new tissue types, the development of self-reporting RNA nanosystems, a description of novel delivery systems, and fundamental biological studies on how delivery systems can be engineered with improved efficacy. Discover more in the PNAS Special Feature: https://ow.ly/nprR50R0Ep6

Hybrid milk EVs mediate oral siRNA delivery: in this article, Driton Vllasaliu and collaborators at King's College London describe the synthesis of hybrid nanovesicles (hybridosomes) from bovine milk extracellular vesicles and liposomes using freeze-thawing methods. Hybridosomes were demonstrated to exhibit lower cytotoxicity and greater stability compared to liposomes, positioning them as a promising approach for the oral delivery of RNA therapeutics https://lnkd.in/dT-nBMRA also authored by Yunyue Zhang, Xiang Luo, NING DING, Mona Belaid and Maya Thanou #extracellularvesicles #exosomes #liposomes #sirna #drugdelivery #Vesiculab

I'm thrilled to announce that I'll host a webinar with Alexander William Jackson in just two weeks! 🚨 Webinar: New Frontiers in ASO and siRNA Bioanalysis 🗓️ Date: Tuesday, 30th July 2024 🕒 Time: 8 am (PDT) / 11 am (EDT) / 3 pm (BST) 📌 Register Now: https://lnkd.in/e7QkfV3c During this webinar, we'll dive into the cutting-edge world of RNA therapeutics, focusing on how to simplify the quantification of RNA therapeutics using Nucleic Acid Nanorobotics (NANs). Whether you're a seasoned professional or just starting out, this session will provide you with the knowledge and tools to excel. 🎯 Key Takeaways: ▶ Learn more about our novel platform, Nucleic Acid Nanorobotics (NANs) ▶ See how this platform is already solving challenging problems for our customers ▶ Participate in an interactive Q&A session where you can ask questions specific to your ASO/RNAi projects and how we can help with your bioanalysis Don’t miss out on this opportunity to learn, engage, and connect with industry peers. We look forward to a dynamic discussion and would love you to join us! Feel free to share this post with your network. We can’t wait to see you there! #Webinar #RNAtherapeutics #Bioanalysis #NucleicAcidNanorobotics

AUG 1st marks World RNA Day (pun intended) In recent years, RNA has gained prominent attention as a therapeutic molecule, playing an important role in drug discovery. Several RNA-based medications have been already approved for clinical use, while others are still under investigation or preclinical trials. These range from RNA interference (RNAi), antisense oligonucleotides (ASOs), and circular RNAs to messenger RNAs (mRNAs). In this way, RNA can work to selectively function on previously-thought undruggable proteins, transcripts, and genes, broadening the range of therapeutic targets. This paves the way for the development of novel treatments against many rare genetic diseases but also oncologic diseases. At InnoSer, we have worked with RNA-based therapeutics in multiple disease models. Find out how our expertise in working with RNA-based therapeutics can help accelerate your research now: https://lnkd.in/eHH4bmZT #RNADay #AUG #RNATherapies #RNAi #mRNA #ASO

Next-generation RNA sequencing unlocks the discovery of novel candidate biomarkers for diagnostic and therapeutic applications, but reproducibility is a key challenge! Integrating multifaceted quality control steps helps to improve design decisions and enhance the confidence and reliability of results. This webinar will demonstrate how a comprehensive QC framework using the Agilent TapeStation system supports a disease-agnostic biomarker discovery program. Register to gain valuable insights: https://bit.ly/3UB3MkK #NGS #RNAseq #DNASequencing

⭐️ Join Us for an Exciting Webinar: "New Frontiers in ASO and siRNA Bioanalysis" Are you interested in the latest advancements in RNA therapeutics? Don't miss our upcoming webinar, where we will explore innovative techniques to simplify the quantification of RNA therapeutics using Nucleic Acid Nanorobotics (NANs). 🗓 Date: Tuesday, 30th July 2024 🕒 Time: 8 am (PDT) / 11 am (EDT) / 3pm (BST) 📍 Location: Zoom What You'll Learn: 💡 Understanding Bioanalysis Challenges — Gain insights into the current challenges in ASO and siRNA bioanalysis, including issues with sensitivity and throughput. 💡 Innovative Bioanalysis Techniques — Discover how NAN technology can improve accuracy, efficiency, and reliability in detecting and quantifying ASOs and siRNA at low concentrations. 💡 Real-World Applications — Learn from real-world case studies showcasing the practical application and performance of the NANs platform. 💡 Interactive Q&A — Engage with experts to discuss your specific bioanalytical challenges and get your questions answered. Don't miss this opportunity to stay ahead in the rapidly evolving field of RNA therapeutics! 👉 Register Now: https://lnkd.in/er-Pw2P8

In the June issue of Drug Development & Delivery, Avidity’s Distinguished Scientist and Strategic Leader, Art Levin, PhD, discusses how we are developing a new class of RNA therapeutics with the potential to precisely target and modify the underlying genetic drivers of diseases. At Avidity, we’re leveraging our proprietary AOC platform to advance our clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (#DM1), facioscapulohumeral muscular dystrophy (#FSHD), and Duchenne muscular dystrophy (#DMD). In the last year, we have shared exciting data from all three programs, further reinforcing the promise of our AOC platform to profoundly improve people's lives by revolutionizing the delivery of RNA therapeutics. Read the full article: https://lnkd.in/eq-MCCVf